Broadcast Date: 
  • Time: 

For years, the biologics industry has struggled with inefficient microbial expression systems for producing proteins and antibodies that they need to manufacture new biopharmaceuticals. Difficulties with low titers, poor product quality, impurities in samples, and capacity constraints are just some of the challenges that scientists have with legacy systems.

Scientists at KBI Biopharma, led by Erik Nordwald, PhD, worked tirelessly for over two years to develop a novel state-of-the-art microbial cell line development platform that addresses these challenges. The new PUREplatform™ solution provides all the functionality that scientists need for optimal therapeutic protein production and development. “The results our development team is seeing with PUREplatform are paving the way for our partners to realize microbial drug substance at a fraction of the scales previously needed, and we hope to see this translate into more efficient cost of goods for at-scale manufacturing,” said J.D. Mowery, Chief Executive Officer of KBI Biopharma. KBI’s PUREcoli™ (part of PUREplatform™ solution), which will be showcased in this webinar, has been shortlisted as a finalist in the “Accelerating Innovation” category at the CPhI Pharma Awards 2023

In this GEN webinar, Dr. Nordwald will discuss how the groundbreaking PUREplatform improves microbial therapeutic protein expression. You’ll learn how PUREplatform can transform microbial drug substance production at a fraction of the scales previously needed. Specific learning objectives include:

• Understanding the inherent challenges and risks associated with microbial biologic development.

• Gaining insights into the constraints faced during microbial biologics development and strategies to streamline the timeline.

• Discovering how PUREcoli plays a pivotal role in mitigating many of these challenges from the outset.

• Learning how PUREcoli addresses complexities in microbial biologic development, setting the stage for smoother processes down the line.

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.

Erik Nordwald
Erik Nordwald, PhD
Associate Director Cell Line Development
KBI Biopharma